SCHEMBL7089999

SCHEMBL7089999

CC1Oc2ccc(C(NC(=O)OC(C)(C)C)C3Cc4ccccc4C3)cc2NC1=S

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
RCE1 Q9Y256 1/20 0.37
EPHX2 P34913 1/20 0.35
HPGD P15428 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
PLA2G1B P04054 1/20 0.35
MAPT P10636 1/20 0.35
XBP1 P17861 1/20 0.35
HTT P42858 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35
IDO1 P14902 1/20 0.33
CXCR3 P49682 1/20 0.32
HSD17B10 Q99714 1/20 0.31
CTSS P25774 1/20 0.31
CTSK P43235 1/20 0.31
SMYD3 Q9H7B4 1/20 0.31
CCKAR P32238 1/20 0.31
CCKBR P32239 1/20 0.31
PARP1 P09874 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7093745 0.86 KDM4E (0.34) KDM4EALDH1A1RCE1EPHX2HPGD
SCHEMBL7094224 0.85 ALDH1A1 (0.34) KDM4EALDH1A1RCE1EPHX2HPGD
SCHEMBL7092653 0.82 KDM4E (0.39) KDM4EALDH1A1RCE1HPGDNPSR1
SCHEMBL7704930 0.82 SMYD3 (0.38) KDM4EALDH1A1RCE1IDO1SMYD3
SCHEMBL7704943 0.80 ALDH1A1 (0.43) ALDH1A1EPHX2HPGDNPSR1MAPT
SCHEMBL7087735 0.77 MC4R (0.36) KDM4EALDH1A1RCE1HPGDNPSR1
SCHEMBL7095873 0.77 CTSS (0.42) KDM4EALDH1A1RCE1HPGDNPSR1
SCHEMBL7092472 0.77 HSD17B10 (0.37) ALDH1A1HPGDNPSR1MAPTXBP1
SCHEMBL7711316 0.77 CTSS (0.38) KDM4EALDH1A1RCE1HPGDNPSR1
SCHEMBL6304809 0.76 MAPT (0.39) KDM4EALDH1A1RCE1HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed